Xurodopa 250 Tablet containing Levodopa and Carbidopa is used for the management of Parkinson's disease and related movement disorders. It helps improve motor control, reduce movement-related symptoms, and support daily functioning.
Levodopa is converted into dopamine in the brain, helping replenish depleted dopamine levels associated with Parkinson's disease, while Carbidopa helps prevent the premature breakdown of Levodopa outside the brain, enhancing its effectiveness.
The tablet is widely prescribed in neurology practice for the long-term management of Parkinsonian symptoms such as tremors, stiffness, slowness of movement, and impaired coordination, leading to consistent prescription demand.
With increasing awareness of neurological disorders and growing demand for effective Parkinson's disease therapies, this product offers strong business potential for retailers and distributors. Its established therapeutic efficacy, proven clinical relevance, and steady market demand make it a reliable product for growth in the neurocare segment.